Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
WEBCombining with ImClone will further strengthen Lilly's growing portfolio of first-in-class and best-in-class pharmaceutical products, enabling Lilly to better support oncologists, with the ultimate goal of delivering better outcomes for cancer patients.
ImClone Systems - Wikipedia
WEBOn November 24, 2008, ImClone was formally acquired by Eli Lilly, with all NASDAQ IMCL shares tendered for $6.5 billion ($70/share). ImClone is now a fully owned subsidiary of Eli Lilly and Company. In 2014 a drug developed by ImClone, tumor angiogenesis inhibitor Cyramza, was approved by the FDA for gastric cancer. [24]
Lilly bids $6.5 bln for ImClone, Bristol bows out | Reuters
WEBOct 7, 2008 · BOSTON/PHILADELPHIA (Reuters) - Eli Lilly and Co has agreed to acquire ImClone Systems Inc for $6.5 billion, outbidding Bristol-Myers Squibb Co and potentially bringing to a close one of the...
Eli Lilly bids $6.5 billion for ImClone | Reuters
WEBOct 6, 2008 · BOSTON/PHILADELPHIA (Reuters) - Eli Lilly and Co has agreed to acquire ImClone Systems Inc for $6.5 billion, outbidding Bristol-Myers Squibb Co and potentially bringing to a close one of the...
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and …
WEBImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed...
Eli Lilly Agrees to Buy ImClone Systems for $6.5 Billion
WEBOct 7, 2008 · Eli Lilly agreed on Monday to pay $6.5 billion to acquire ImClone Systems, the biotechnology company that is controlled by Carl C. Icahn and whose stock was involved in the insider trading...
ImClone backs $6.5bn Eli Lilly bid - Financial Times
WEBOct 7, 2008 · Eli Lilly has agreed to take over ImClone for $70 a share in cash, valuing the cancer drug maker at about $6.5bn and trumping an unsolicited bid from Bristol-Myers Squibb.
Eli Lilly to acquire ImClone for $70 a share - MarketWatch
WEBOct 6, 2008 · Eli Lilly says it plans to buy cancer-drug developer ImClone Systems for $70 a share, or about $6.5 billion, in an all-cash deal that is not subject to any financing conditions.
Lilly Finalizes Acquisition of ImClone Systems
WEBNov 24, 2008 · Eli Lilly and Company completed its acquisition of ImClone Systems today. ImClone Systems is now a wholly owned subsidiary of Lilly.
Eli Lilly and Company Completes Acquisition of ImClone Systems ...
WEBNov 24, 2008 · Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and …